SSY GROUP (02005): Nemonoxacin Malate Has Been Approved by the National Medical Products Administration for Registration as an API Used in Marketed Formulations
SSY GROUP (02005) announced that the group's nemonoxacin malate has been approved by China's National Medical Products Administration for registration as an API used in marketed formulations.
SSY GROUP (02005) announced that the group's nemonoxacin malate has been approved by China's National Medical Products Administration for registration as an API used in marketed formulations.
Nemonoxacin malate is an anti-infective drug, primarily used for the treatment of adult community-acquired pneumonia caused by nemonoxacin-susceptible Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, as well as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process
Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares
CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process
Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares
CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
